United States-based AbbVie has failed to meet its goal in a phase three trial named DBL3001 for its Ibrutinib (IMBRUVICA) in untreated diffuse large B-cell lymphoma patients, it was reported yesterday.
The product is a first-in-class Bruton's tyrosine kinase inhibitor jointly developed and commercialised by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc (Janssen). It has been available in the United States since 2013 and is FDA-approved for use in five B-cell blood cancers and chronic graft-versus-host-disease for a total of eight FDA-approved indications.
The DBL3001 study assessed the addition of ibrutinib to a chemotherapy regimen that includes five different agents used in combination, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), versus R-CHOP plus placebo. The study was conducted in a subset of untreated DLBCL patients identified to have the non-germinal center B cell (GCB) or activated B-cell (ABC) subtypes of this disease. Patients identified with non-GCB or ABC subtypes typically have poorer treatment outcomes and have greater unmet medical need. At conclusion of the study, data collected found that ibrutinib plus the chemotherapy regimen, R-CHOP, was not superior to R-CHOP alone, and that the study did not meet its primary endpoint of improving event-free survival (EFS) in the targeted patient population.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer